Group 1 - The core viewpoint of the articles highlights the recent policy initiatives in China aimed at accelerating the development and accessibility of innovative drugs, with a focus on improving the process from drug approval to patient access [1][3][5][7] Group 2 - In July, the National Healthcare Security Administration and the National Health Commission issued measures to support high-quality development of innovative drugs, introducing 16 initiatives to invigorate the sector [1] - Shanghai has implemented policies to streamline the process for innovative drugs to reach hospitals, mandating that the entire process be completed within 15 working days and ensuring that costs for national negotiation drugs do not count against the annual medical insurance quota [3] - Beijing has expanded payment channels for innovative medicines, establishing a dynamic adjustment mechanism for a special drug list, which has been upgraded to 121 types for 2025, and has facilitated rapid listing of 51 innovative drugs on the procurement platform [5] - The National Healthcare Security Administration has adjusted the drug list seven times, incorporating a total of 149 innovative drugs into the medical insurance directory, significantly reducing the time from drug approval to insurance coverage from approximately 5 years to around 1 year [7]
让好药更快惠及患者：政策组合拳打通创新药应用“最后一公里”
Yang Shi Wang·2025-09-17 03:15